Kristen Pogue, PharmD, FCCP, BCCP

Clinical Pharmacist Specialist in Cardiology
Residency Program Director: PGY2 Cardiology
Clinical Associate Professor of Pharmacy
Rotation(s) Offered: General cardiology, Advanced Heart Failure/Transplant, Medical Ventricular Assist Device


In concert with Sarah Adie, Sarah Hanigan, and Claire Walter I provide clinical services to the general cardiology, advanced heart failure/transplant, medial ventricular assist device, and electrophysiology medical services. I co-chair the anticoagulation management subcommittee and also serve on the medication reconciliation oversight committee. I teach VTE/anticoagulation and pulmonary hypertension within the therapeutics sequence at the college of pharmacy and also teach within the nursing school.

Pharmacy School Attended: Wayne State University (2006)

Other Training:

  • PGY1 Pharmacy: University of Michigan 
  • PGY2 Cardiology: University of Michigan

Areas of Interest

Pulmonary arterial hypertension, antithrombotics, advanced heart failure, mechanical circulatory support

Honors & Awards

2017: Preceptor of the Year, University of Michigan College of Pharmacy 

Published Articles or Reviews

  • Hanigan S, Das J, Pogue K, Barnes GD, DorschMP. The real world ues of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 2020;():1-8. DOI: 10.1007/s11239-020-02037-3.
  • Coons JC, PogueK,Kolodziej AR, Hirsch GA, George MP. Pulmonary arterial hypertension: a pharmacotherapeutic update. Curr Cardiol Rep2019;21:141.
  • Adie S, Bitar A, Hanigan S, PogueK,Koelling T, Dorsch M. Real-world prevalence of adverse events after initiating sacubitril/valsartan compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure. J Card Fail2019;25:412-3.
  • Rollins A, Hanigan S, PogueK,Renner E, Barnes G, Dorsch M. Identifying clinical predictors of switching from direct oral anticoagulants to warfarin. Clinical Medicine Insights: Therapeutics2019;11:1-6.
  • Smith ZR, Rangarajan K, Barrow J, Carter D, Coons JC, Dzierba AL, Falvey J, Fester KA, Guido MR, Hao D, Ou NN, PogueKT,MacDonald NC. Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi method. Am J Health Syst Pharm 2019;76:153-65
  • Early C, Park J, Dorsch M,PogueK,Aaronson K, Hanigan S. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile. Transpl Infect Dis 2016;18:714-20.
  • Kaminsky BM,PogueKT,Hanigan S, Koelling TM, Dorsch MP. Effects of total dose infusion of iron intravenously in patients with acute heart failure and anemia (hemoglobin < 13 g/dL). Am J Cardiol 2016;117:1942-6.
  • Macauley TE, Covell MB,PogueKT. An update on the management of pulmonary arterial hypertension and the pharmacist’s role. J Pharm Pract2016;29:67-76.
  • Pogue KTand Walter CP. Pulmonary Arterial Hypertension. In: PharmacotherapySelf-Assessment Program, 2016 Book 1. Cardiology. Lenexa, KS: American College of Clinical Pharmacy:in press.